Biofrontera AG (ETR:B8FK)

Germany · Delayed Price · Currency is EUR

2.260

-0.080 (-3.42%)

Jul 15, 2026, 5:37 PM CET

-8.87% (1Y)

Market Cap	13.73M -5.8%
Revenue (ttm)	13.63M +11.9%
Net Income	-2.44M
EPS	-0.40
Shares Out	6.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	882
Open	2.280
Previous Close	2.340
Day's Range	2.260 - 2.370
52-Week Range	2.210 - 2.960
Beta	-0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic produ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1997

Employees 69

Stock Exchange Deutsche Börse Xetra

Ticker Symbol B8FK

Full Company Profile

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -3.97 million, -8.85% less than in 2024.

Financial Statements